Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Spero Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Spero Therapeutics, Inc.

SPRO

Spero Therapeutics, Inc.

About Spero Therapeutics, Inc.

Spero Therapeutics is a biopharmaceutical company focused on developing novel treatments for rare and multi-drug resistant bacterial infections. Its pipeline includes oral and IV antibiotics targeting serious infections like cUTI, HABP/VABP, and NTM pulmonary disease. The company collaborates with partners like GSK and Meiji, leveraging proprietary technology and strategic licensing to address high unmet medical needs in infectious diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Spero Therapeutics, Inc.

1
1
Spero Therapeutics, Inc. Spero Therapeutics Reports Revenue Decline to $258,000 in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Spero Therapeutics, Inc. Spero Therapeutics Reports $8.6M Net Income and Operational Updates in Annual Filing

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Spero Therapeutics, Inc. Spero Therapeutics Reports Significant Revenue Decline and Strategic Restructuring in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Spero Therapeutics, Inc. Spero Therapeutics Reports 38.9% Revenue Growth and Improved Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Spero Therapeutics, Inc. Spero Therapeutics Reports $13.9 Million Net Loss and 37% Revenue Decline in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Spero Therapeutics, Inc. Spero Therapeutics Reports $68.6 Million Net Loss for 2024, Decreased Collaboration Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Spero Therapeutics, Inc. Spero Therapeutics Reports Q3 2024 Financial Results, Announces Restructuring Plan and Workforce Reduction

Via official filing (AI summary) | over 1 year ago | 0 comments